CD34 and Cirrhosis: The results of this trial provide important insight into the safety, feasibility, and potential efficacy of G–CSF–mobilized autologous CD34+ cell therapy for patients with DC type C. Additionally, autologous PB-CD34+ cell infusion therapy may be a beneficial treatment for DC, with the potential to reverse it into compensated cirrhosis, thereby preventing the need for liver transplantation.